Status:
UNKNOWN
Safety and Efficacy of Human Mesenchymal Stem Cells for Treatment of Liver Failure
Lead Sponsor:
Beijing 302 Hospital
Conditions:
Liver Failure
Mesenchymal Stem Cells
Eligibility:
All Genders
18-70 years
Phase:
PHASE1
PHASE2
Brief Summary
Liver failure (LF) is a dramatic clinical syndrome with massive necrosis of liver cells. and liver transplantation is the only available therapeutic option for patients suffering with this condition. ...
Detailed Description
Liver failure (LF) is a severe life-threatening condition, and is a dramatic clinical syndrome with massive necrosis of liver cells, and liver transplantation is the only available therapeutic option ...
Eligibility Criteria
Inclusion
- Aged 18-70 years
- Liver failure
- Negative pregnancy test (female patients in fertile age)
- Written consent
Exclusion
- Hepatocellular carcinoma or other malignancies
- Severe problems in other vital organs(e.g.the heart,renal or lungs)
- Pregnant or lactating women
- Severe bacteria infection
- Anticipated with difficulty of follow-up observation
- Other candidates who are judged to be not applicable to this study by doctors
Key Trial Info
Start Date :
March 1 2009
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
March 1 2014
Estimated Enrollment :
70 Patients enrolled
Trial Details
Trial ID
NCT01218464
Start Date
March 1 2009
End Date
March 1 2014
Last Update
May 31 2013
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Beijing 302 Hospital
Beijing, Beijing Municipality, China, 100039